<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722551</url>
  </required_header>
  <id_info>
    <org_study_id>2015-14</org_study_id>
    <nct_id>NCT02722551</nct_id>
  </id_info>
  <brief_title>CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>The RELIEF Trial: REduction or eLimination of mItral rEgurgitation in Degenerative or Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter
      Mitral Valve
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, prospective, single-arm, and non-randomized study designed to
      evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve with
      transapical and transseptal delivery systems in patients with degenerative or
      functional/ischemic mitral regurgitation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from major adverse cardiac and cerebrovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>MACCE; all-cause mortality, myocardial infarction, stroke, renal failure, and conversion to surgery per MVARC definitions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from individual adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>% Freedom from individual adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Number of patients with improvement in NYHA class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test:</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Increase in distance (m) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in mitral regurgitation (MR) grade:</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Number of patients with reduction in MR grade from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Technical success per MVARC criteria (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Device success per MVARC criteria (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Procedure success per MVARC criteria (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient success</measure>
    <time_frame>30 days, 3 months, 6 months, 12 months</time_frame>
    <description>Patient success per MVARC criteria (%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve</intervention_name>
    <description>Replacement of the mitral valve through a transcatheter approach</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA ≥ II

          -  Moderate/severe or severe mitral regurgitation

          -  Prohibitive risk for open-heart surgery

          -  Meets anatomical criteria

        Exclusion Criteria:

          -  Unsuitable anatomy

          -  Need for emergent or urgent surgery

          -  Prior mechanical aortic valve replacement

          -  Any prior surgical or transcatheter repair (excluding balloon valvuloplasty) or
             replacement of the mitral valve

          -  Preexisting device in the left ventricular apex

          -  Clinically significant, untreated coronary artery disease

          -  Limited life expectancy (&lt; 12 months)

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Sondergaard</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Trekell</last_name>
    <phone>(949) 250-2672</phone>
    <email>jill_trekell@edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital, University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Jian Ye, MD</last_name>
      <phone>604-806-9349</phone>
      <email>jye@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dr. John Webb, MD</last_name>
      <phone>604-806-9349</phone>
      <email>webb@providencehealth.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Jian Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Mark Peterson, MD</last_name>
      <phone>416-864-3086</phone>
      <email>PetersonM@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Neil Fam, MD</last_name>
      <phone>416-864-3086</phone>
      <email>FamN@smh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Mark Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Neil Fam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Eric Horlick, MD</last_name>
      <phone>416-340-3835</phone>
      <email>Eric.Horlick@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dr Mark Osten, MD</last_name>
      <phone>416-340-4615</phone>
      <email>ostenm@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Eric Horlick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Mark Osten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de recherche Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Francois Dagenais, MD</last_name>
      <phone>1-418-656-8711</phone>
      <phone_ext>2323</phone_ext>
      <email>francois.dagenais@chg.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dr Eric Dumont, MD</last_name>
      <phone>1-418-656-8711</phone>
      <phone_ext>2323</phone_ext>
      <email>Eric.Dumont@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Dr Francois Dagenais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Eric Dumont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Sondergaard, MD</last_name>
      <phone>+45 3545 2992</phone>
      <email>lars.soendergaard.01@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Holme, MD</last_name>
      <email>susanne.juel.vedel.holme@rh.regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Sondergaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne Holme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Modine, MD</last_name>
      <phone>+33 6 11 83 18 21</phone>
      <email>thomas.modine@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Arnaud Sudre, MD</last_name>
      <phone>+33 6 12 54 92 86</phone>
      <email>arnaud.sudre@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Modine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Sudre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Walther, MD</last_name>
      <phone>+49 6032 996-2501</phone>
      <email>t.walther@kerckhoff-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Helge Möllmann, MD</last_name>
      <phone>+49 6032 996 2246</phone>
      <email>h.moellmann@kerckhoff-klinik.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Walther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helge Möllmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsche Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volkmar Falk, MD</last_name>
      <phone>+49 30 4593-2000</phone>
      <email>falk@dhzb.de</email>
    </contact>
    <contact_backup>
      <last_name>Jörg Kempfert, MD</last_name>
      <phone>+49 30 4593 2085</phone>
      <email>Kempfert@dhzb.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Kempfert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Centre</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hendrik Treede, MD</last_name>
      <email>hendrik.treede@uk-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich Schäfer, MD</last_name>
      <email>u.schaefer@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hendrik Treede, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Schäfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der UniKlinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Baldus, MD</last_name>
      <phone>+ 49 221 478-32511</phone>
      <email>stephan.baldus@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Thorsten Wahlers, MD</last_name>
      <email>thorsten.wahlers@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Baldus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thorsten Wahlers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Herzzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Linke, MD</last_name>
      <phone>+49.341.865.1427</phone>
      <email>Axel.Linke@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Axel Linke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ottavio Alfieri, MD</last_name>
      <email>alfieri.ottavio@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Colombo, MD</last_name>
      <email>colombo.antonio@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Ottavio Alfieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita di Roma Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gian Paolo Ussia, MD</last_name>
      <email>gian.paolo.ussia@uniroma2.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Romeo, MD</last_name>
      <email>romeocerabino@tin.it</email>
    </contact_backup>
    <investigator>
      <last_name>Gian Paolo Ussia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Romeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nico van Mieghem, MD</last_name>
      <phone>+31 10 703 52 60</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Arie Pieter Kappetein, MD</last_name>
      <phone>+31 10 703 44 76</phone>
      <email>a.kappetein@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Nico van Mieghem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arie Pieter Kappetein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>InselSpital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Windecker, MD</last_name>
      <phone>41-31-632-9591</phone>
      <email>stephan.windecker@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Thierry Carrel, MD</last_name>
      <email>thierry.carrel@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Windecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Carrel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>March 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral</keyword>
  <keyword>Regurgitation</keyword>
  <keyword>Insufficiency</keyword>
  <keyword>Degenerative</keyword>
  <keyword>Functional</keyword>
  <keyword>Primary</keyword>
  <keyword>Secondary</keyword>
  <keyword>Organic</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>TMVR</keyword>
  <keyword>TMVI</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Mitral valve</keyword>
  <keyword>Transapical</keyword>
  <keyword>Transfemoral</keyword>
  <keyword>Trans-septal</keyword>
  <keyword>Transeptal</keyword>
  <keyword>Severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
